Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2017 - 07 - 05
点击次数: 0
Positions: founder and CEO
Company: Immunwork, Inc
个人简介:
Dr. Chang cofounded Tanox in Houston, Texas in 1986 and invented in 1987 the anti-IgE therapy, leading to the development of talizumab, omalizumab (Xolair), and ligelizumab. Xolair has been approved for treating severe allergic asthma and severe chronic spontaneous urticaria. He returned to Taiwan in 1996 to serve as the dean of the College of Life Sciences, Tsing Hua University, and subsequently the President of Development Center for Biotechnology. He was a Distinguished Research Fellow in the Genomics Research Center in Academia Sinica in 2006-2015. His group discovered CemX domain on membrane IgE and developed an anti-CemX antibody UB221, which is in clinical development. Dr. Chang is now leading Immunwork to develop “T-E technology” platform, which can be used to create new drugs with both targeting and effector moieties. More than 20 new drugs have been designed for applications in oncology, autoimmune, infectious, CNS diseases, and other disease
发布时间: 2017 - 07 - 05
点击次数: 0
Positions: partner
Company: FountainVest
个人简介:
Dianna currently is a core healthcare member of FountainVest Partners, a leading China focused Private Equity with $4.5 Billion under management. FountainVest’s LPs are global top tier pension funds, Endowments, Sovereign funds and etc. Dianna has 17 years of work experiences, among which 14 years were in the healthcare industry. Her role went from a healthcare specialized consultant to a pharmaceutical corporate senior executive, and finally to be a healthcare investor.  Before joining FountainVest, Dianna worked at Fidelity Growth Partners Asia (FGPA), focusing on early stage healthcare investment. Prior to that, Dianna was a Vice President at Boehringer Ingelheim China. She was in charge of Business Development and New Product Planning, focusing on M&A, licensing, collaborations deals and strategic product launch planning. From 2005-2008, Dianna worked at McKinsey & Company Shanghai and New Jersey offices in healthcare practice. In the capacity of Engagement Manager, Dianna has worked on more than a dozen of projects in drugs, vaccines, medical devices, distribution and etc., During 1999-2005, Dianna worked at Goldman Sachs Asia in Hong Kong and The Boston Consulting Group Shanghai office.  Dianna holds a MBA degree from the Wharton School of Business at the University of Pennsylvania.
发布时间: 2017 - 07 - 05
点击次数: 0
Positions: Executive Chairman of FMD
Company: Fountain Medical (TIANJIN) Co., Ltd.
个人简介:
□ MPH in Health Policy and Management from Harvard University □ MA in Health Care Administration from The Wharton School, University of Pennsylvania □ MD from Peking Union Medical College □ 20 years of experience in the Pharma industry □ Head of Global Safety Assessment and Clinical Drug Development at Sigma-Tau USA (largest pharmaceutical company in Italy) □ Vice President of Quintiles Transnational Corporation. □ Long time advisor for the CFDA □ New Drug Review Committee □ Member of grant review committee for the National Key Drug Development
发布时间: 2017 - 07 - 05
点击次数: 0
Positions: Director
Company: Ally Bridge LB Healthcare Fund
个人简介:
Dr. Bin Li is the founder and CIO of ABG-LB Healthcare Fund and a partner of Ally Bridge Group, a global healthcare investment fund based in Hong Kong. Previously, he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley and led the coverage of Greater China healthcare industry. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he had been ranked as the top analyst in China healthcare industry by the most widely recognized investor surveys. He was ranked No. 1 Asia Healthcare Analyst by the Institutional Investor (II) for seven consecutive years (2008-2014) and No.1 China Healthcare Analyst each year by II since the poll started in 2010 (2010-2014). He was also repeatedly ranked as No. 1 Asia Healthcare Analyst by all other independent investor surveys including Greenwich and Asiamoney. In addition, he was rated as No. 1 in Wall Street Journal's Best Asia Healthcare Analysts poll for his stock selection in 2010. Before joining Morgan Stanley, he was a senior healthcare research analyst at Merrill Lynch (Hong Kong) and responsible for the firm’s stock research efforts on Asia healthcare. Before moving to Hong Kong in 2007, he was a key member of a top-rank US pharmaceutical research team at Merrill Lynch based in New York. Dr. Li has over 20-year experience in healthcare industry. He received his Ph.D. in biochemistry and MBA from New York University and bachelor degree from Fudan University, China. Prior to his sell-side career, he worked at Merck Research Laboratory as a scientist and published papers on peer-reviewed science journals.
42页次7/11首页Previous...  234567891011Next尾页